Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Triple-negative breast cancer
The diameter of the primary tumor must be greater than 2cm, and the clinical stage should be II-III
There is sufficient primary organ function
The ECOG (PS) score is 0 or 1
Expected survival ≥ 6 months
The serum pregnancy test was negative. Use highly effective methods of contraception during the study period and for 180 days after the last dose of the study drug, and do not breastfeed
You may not be if
Bilateral breast cancer
There is a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)
A history of invasive or metastatic breast cancer
Any malignancy diagnosed within 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma
There is an immune deficiency disease
The presence of any autoimmune disease that still requires treatment or a history of prior autoimmune disease
Clareo Health | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）
